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Key points 
Question 
Is the genetic liability to psychotic experiences shared with schizophrenia and/or other 
neuropsychiatric disorders and traits? 
Findings 
Genetic correlation, polygenic risk score, and copy number variation analyses indicated a shared 
genetic aetiology between psychotic experiences and major depressive disorder, schizophrenia, 
bipolar disorder, and neurodevelopmental disorders. GWAS analyses identified four genetic loci 
associated with psychotic experiences including loci in ANK3 and CNR2. 
Meaning 
Findings suggest the genetic aetiology of psychotic experiences is shared with several psychiatric 
disorders, which include, but is not specific to, schizophrenia.  
Suggested Tweet 
Psychotic experiences in UK Biobank have shared genetic aetiology with schizophrenia, 
depression, bipolar disorder and neurodevelopmental disorders. 






Psychotic experiences, such as hallucinations and delusions, are reported by approximately 5%-
10% of the general population, though only a small proportion develop psychotic disorders such 
as schizophrenia. Studying the genetic aetiology of psychotic experiences in the general 
population, and its relationship with the genetic aetiology of other disorders, may increase our 
understanding of their pathological significance. 
Objective 
To determine whether genetic liability to psychotic experiences is shared with schizophrenia 
and/or other neuropsychiatric disorders and traits. To identify genetic loci associated with 
psychotic experiences. 
Design 
Analyses of genetic correlation, polygenic risk scores (PRS), and copy number variation (CNV) 
were used to assess whether genetic liability to psychotic experiences is shared with 
schizophrenia and/or other neuropsychiatric disorders and traits. GWAS analyses of psychotic 
experience phenotypes were conducted to identify novel genetic loci. 
Setting  
The population-based UK Biobank cohort. 
Participants 
Participants in the final analyses included 6123 individuals reporting any psychotic experience, 
2143 individuals reporting distressing psychotic experiences, and 3337 individuals reporting 
multiple occurrence psychotic experiences. 121,843 individuals who did not report a psychotic 
experience formed the comparator group. Individuals with a psychotic disorder were excluded 
from all analyses.  
Main Outcomes and Measures 




The study included a total of 127,966 participants with a mean age of 64 (sd =7.6) and of whom 
56% were female. Psychotic experiences were genetically correlated with major depressive 
disorder, schizophrenia, autism spectrum disorder, and ADHD. PRS analyses identified 
associations between psychotic experiences and genetic liability for major depressive disorder, 
schizophrenia, bipolar disorder, autism spectrum disorder and ADHD. Individuals reporting 
psychotic experiences had an increased burden of CNVs previously associated with 
schizophrenia (OR=2.04, 95% CI=1.39-2.98, p=2.49x10-4) and of those associated with 
neurodevelopmental disorders more widely (OR=1.75, 95% CI=1.24-2.48, p=1.41x10-3). GWAS 
identified four significantly associated loci including a locus in Ankyrin-3 (ANK3, OR=1.16, 95% 
CI=1.10-1.23, p=3.06 x 10-8) with any psychotic experience and a locus in cannabinoid receptor 2 
gene (CNR2, OR=0.66, 95% CI=0.56-0.78, p=3.78x10-8) with distressing psychotic experiences. 
The GWAS of any psychotic experience had a low SNP-based heritability (r2=1.71%). 
Conclusions and Relevance 
In the largest genetic-association study of psychotic experiences from the population-based UK 
Biobank sample, we found support for a shared genetic aetiology between psychotic 




Psychotic experiences, such as hallucinations and delusions, are features of psychiatric 
disorders, for example schizophrenia, but they are also reported by approximately 5%-10% of 
the general population1,2. Psychotic experiences are only considered to be symptoms of 
psychiatric illness if they co-occur with other features of that disorder, including some aspect of 
psychosocial impairment. It is currently unclear whether psychotic experiences in the general 
population are (i) on a spectrum that at the extreme relates specifically to schizophrenia, (ii) 
largely unrelated to the psychotic symptoms experienced in schizophrenia and other major 
mental disorders, or (iii) related to liability to major mental disorders more generally.  
Twin studies and genome-wide association studies (GWAS) have provided evidence that 
psychotic experiences are heritable (30-50% from twin studies3-5, 3-17% for SNP-heritability 
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estimates6,7), indicating that common genetic variants play a role in their aetiology. There have 
been three GWAS of psychotic experiences to date in adolescent samples7-9 and no reported 
genome-wide significant findings. Whilst there was an initial assumption that psychotic 
experiences in adolescence would specifically increase the risk for schizophrenia in later life, 
epidemiological evidence suggests a non-specific increased risk for a broader 
psychopathology10. However, to date no study has found strong evidence for association 
between genetic liabilities for schizophrenia or any other mental disorder with psychotic 
experiences7,8,11-13.  
Although many individuals with a lifetime history of psychotic experiences have their first 
experience in adolescence, nearly a quarter of first onset psychotic experiences occur after 40 
years of age14. Our aims were to use the UK Biobank to (i) identify genetic loci associated with 
psychotic experiences reported by adults in a population-based study, and (ii) to determine 
whether genetic liability to psychotic experiences is shared with schizophrenia and/or other 




Study individuals were from the UK Biobank, a large prospective population-based cohort study 
of approximately 500,000 individuals aged between 40-69 who were recruited from across the 
UK between 2006-201015. The North West Multi-Centre Ethics Committee granted ethical 
approval to UK Biobank and all participants provided informed consent. This study was 
conducted under UK Biobank project numbers 13310 and 14421. 
Psychotic experiences phenotypes 
A Mental Health Questionnaire (MHQ) was sent to all participants in 2016-2017 who provided 
an email address and was completed by a total of 157,397 individuals (46% of those emailed, 
31% of the total UK Biobank sample). For psychotic experiences, participants were asked about 
previous experience of visual hallucinations, auditory hallucinations, delusions of reference, 
delusions of persecution, how often these experiences occurred and how distressing they found 
them (see eAppendix 1). Individuals with a diagnosis of schizophrenia, bipolar disorder or any 
other psychotic disorder were identified using all available sources (hospital records, death 
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records, self-report at the interview or from the MHQ) and were excluded from all analyses (full 
details in eMethods 1).  
We selected three primary phenotypes for GWAS (eFigure 1): (i) any psychotic experience 
defined as a positive response to any of the four symptom questions (UKB field IDs: 20471, 
20463, 20474, 20468), (ii) a distressing psychotic experience, defined as any psychotic experience 
that was rated as ‘a bit’, ‘quite’ or ‘very’ distressing (UKB field ID: 20462), (iii) multiple 
occurrence psychotic experiences defined as any psychotic experience that occurred on more 
than one occasion (UKB field IDs: 20473, 20465, 20476, 20470). As a comparator group, we 
included individuals who provided a negative response to all four psychotic experience 
symptom questions. In addition, we investigated each individual psychotic experience symptom 
for association with PRS.  
Genetic data 
Genetic data for the study participants was provided by UK Biobank and the imputation and 
quality control procedures are fully described elsewhere16. The data release contained 488,377 
participants assayed on either the UK Biobank Axiom or the UK BiLEVE Axiom purpose-built 
arrays at the Affymetrix Research Services Laboratory. Standard quality control procedures were 
applied prior to imputation using Haplotype Reference Consortium (HRC)17 and UK10K 
haplotype reference18 panels. We applied additional quality control filters to select high quality 
SNPs19; minor allele frequency (MAF) > 0.01, imputation score (INFO) > 0.8, missingness < 0.05, 
Hardy-Weinberg equilibrium (HWE) < 1 x 10-6, and removed SNPs imputed by the UK10K 
haplotype reference18 dataset in accordance with guidance from the UK Biobank (URL: 
http://www.ukbiobank.ac.uk/2017/07/important-note-about-imputed-genetics-data/). One 
member from each related pair with a kinship coefficient > 0.15 was excluded from analyses, 
preferentially retaining individuals that had experienced a psychotic experience, and were 
otherwise removed at random.  
Analyses were restricted to individuals with a self-reported British and Irish background (UKB 
field ID: 21000) and principal components supplied by UK Biobank16 (UKB field ID: 22009) were 
used to make additional exclusions and control for population structure (described in eMethods 




To identify genetic risk variants for psychotic experiences, association analysis was performed in 
SNPTEST (v2.5.4)22 using bgen v1.2 imputed dosage data23. Over 7.5 million SNPs were included 
in each GWAS. An additive logistic regression model was used including as covariates 
genotyping array, the top five principal components (as recommended for most GWAS 
approaches24), and any additional principal components from the first 20 that were nominally 
associated (p < 0.05) with the GWAS phenotype in a logistic regression. To obtain relatively 
independent index SNPs, linkage disequilibrium (LD) clumping was performed in PLINK25 (r2 < 
0.1, p < 1x10-4, window size < 3MB) for each GWAS using a reference panel of 1000 randomly 
selected UK Biobank individuals with confirmed European ancestry. Functional annotation was 
conducted using FUMA26. LDSC27 was used to calculate the LD score intercept and heritability on 
the observed scale using the summary statistics from each psychotic experience GWAS.  
Validation analyses in ALSPAC cohort 
To assess the reproducibility of the psychotic experience GWAS, we used the summary statistics 
from the any psychotic experience GWAS to target psychotic experiences in the Avon 
Longitudinal Study of Parents and Children (ALSPAC) cohort28,29, which have been previously 
described11,30. The psychotic experience PRS was generated for each ALSPAC participant using 
the widely used method31 and logistic regression was used to test for association between PRS 
and psychotic experiences reported at age 12 and 18 years (eMethods 3).  
Genetic correlations 
LDSC27,32 was used to calculate the genetic correlation between the any psychotic experience 
GWAS and other psychiatric and personality traits. External GWAS datasets (that did not include 
UK Biobank where possible) used to generate the correlations included schizophrenia33, bipolar 
disorder34, major depressive disorder35, attention deficit/hyperactivity disorder (ADHD)38, 
autism spectrum disorder39, neuroticism36 and intelligence37. A Bonferroni correction was 
applied to control for multiple testing. 
Polygenic risk scores 
PRSs were generated to investigate additional psychotic experience phenotypes that were not 
sufficiently powered for genetic correlation analyses. We selected the same summary statistics 
used for genetic correlations to create the risk scores for UK Biobank participants using the 
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method described by the PGC31 and detailed in eMethods 4. The intelligence GWAS summary 
statistics used in this study specifically excluded participants from UK Biobank (n=74,214 
individuals remaining). None of the other training sets included UK Biobank as a contributing 
sample, although we were not able to test for duplicates at the genotype level and so cannot 
rule these out. Given this potential for sample overlap with the training sets, PRS results should 
be treated with a degree of caution and are used primarily to support and extend findings from 
genetic correlation analysis (which allows for overlapping samples). The primary analysis used 
standardised scores generated from SNPs with a discovery sample p-value threshold of p ≤ 0.05, 
but associations at 10 other p-value thresholds were also tested. A logistic regression model was 
used to test the association of each PRS with various psychotic experience phenotypes, 
covarying for the first five principal components and genotyping array. Copy number variation 
CNV calling for UK Biobank has been described in detail elsewhere41 and detailed in eMethods 
5. We compared carrier status of rare CNVs previously associated with (i) schizophrenia43 and (ii) 
neurodevelopmental disorders more widely44 with the three primary psychotic experience 
phenotypes used for GWAS. Association analyses were carried out using logistic regression and 
included age, sex and genotyping array as covariates.  
 
Results  
A total of 7803 (5.0%, 60.0% female, mean age 63 (SD=7.7)) individuals from UK Biobank who 
completed the MHQ reported at least one psychotic experience, 3012 individuals rated the 
psychotic experience as distressing, and a total of 4388 reported multiple occurrences of at least 
one psychotic experience. A total of 147,461 individuals (56.0% female, mean age 64 (SD=7.6)) 
who reported no psychotic experiences constituted the comparison group for our association 
analyses. The mean age of the first psychotic experience was 31.6 years (SD=17.6) (eFigure 4) 
with 2341 (35.2%) first occurring before the age of 20 or for as long as the participant could 
remember, 2137 (32.1%) between the ages of 20-39, and 2176 (32.7%) between the ages of 40 
and 76. We excluded 198 individuals who had a diagnosis of schizophrenia, 818 with bipolar 
disorder, and 346 with other psychotic disorders from all genetic analyses (detailed in 




The GWAS of any psychotic experience in 6123 cases and 121,843 controls (following QC, 
exclusions detailed in eMethods 6) identified two variants that were associated at the genome-
wide significance (GWS) level of p < 5x10-8 (Figure 1, Table 1, λGC=1.05, LD Score regression 
intercept=1.00); rs10994278, an intronic variant within Ankyrin-3 (ANK3, OR=1.16, 95% 
confidence intervals (CI)=1.10-1.23, p=3.06x10-8), and intergenic variant rs549656827 (OR=0.61, 
95% CI=0.50-0.73, p=3.30x10-8).  
A second GWAS restricting the cases to 2143 individuals with distressing psychotic experiences 
identified two GWS variants (Table 1, λGC=1.03, LD Score intercept=1.01); rs75459873 intronic to 
cannabinoid receptor 2 (CNR2, OR=0.66, 95% CI=0.56-0.78, p=3.78x10-8) and intergenic variant 
rs3849810 (OR=1.22, 95% CI=1.13-1.31, p=4.55x10-8). 
The third GWAS restricting the cases to 3337 individuals who reported multiple occurrences of 
psychotic experiences did not identify any associated variants at GWS (λGC=1.03, LD Score 
intercept=1.00). QQ plots for each GWAS are displayed in eFigure 5 and LocusZoom plots for 
each GWS loci are provided in eFigure 6.  
SNP based heritability estimates calculated by LDSC27 for the GWAS of any psychotic experience 
was h2=1.71% (95% CI=1.02-2.40%). The other GWAS analyses did not requirements (case 
n>5,000 and Z-score>445) for heritability or genetic correlation analyses with LDSC. None of the 
associated regions from the any psychotic experience and distressing psychotic experience 
GWAS showed evidence of colocalization46 with schizophrenia33, bipolar disorder34 or major 
depressive disorder35.  
Validation analyses in ALSPAC 
There was evidence of association between the PRS calculated using the any psychotic 
experience GWAS from UK Biobank at the p-value threshold of ≤0.5 and definite psychotic 
experiences between ages 12 and 18 years in ALSPAC (OR=1.13; 95% CI=1.02-1.25; R2=0.002; 
p=0.02). This finding was consistent for thresholds below p<0.05 and when using measures from 
age 18 years only (eFigure 7, eTable 1). However, the psychotic experiences PRS was also 
associated with the presence of major depressive disorder at age 18 (OR = 1.19; 95% CI=1.05-
1.35; R2=0.004; p=0.01).  
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Relationship between association at CNR2 and cannabis use  
We investigated, but found no evidence for, a mediating or moderating effect of cannabis use 
on the association between distressing psychotic experiences and rs75459873 at the 
cannabinoid receptor gene CNR2. Cannabis use itself (UKB field id: 20453) was significantly 
associated with distressing psychotic experiences (OR=1.36, 95% CI=1.32-1.40, p=9.16 x 10-88), 
but rs75459873 was not associated with cannabis use (OR=0.99, 95% CI=0.95-1.04, p=0.70). 
Furthermore, the association between rs75459873 and distressing psychotic experiences was 
unchanged in a model including cannabis use as a covariate (OR=0.62, 95% CI=0.52-0.75) or as 
an interaction term (OR=0.59, 95% CI=0.48-0.73, interaction p=0.31).  
Genetic correlations  
Significant genetic correlations (rg) were observed between any psychotic experience and major 
depressive disorder (rg=0.46, p=4.64x10-11), autism spectrum disorder (rg=0.39, p=1.68x10-4), 
ADHD (rg=0.24, p=4.61x10-3) and schizophrenia (rg=0.21, p=7.29x10-5). Figure 2 displays these 
genetic correlations and eTable 2 details the full results. The other psychotic experience GWAS 
analyses did not meet requirements45 for genetic correlation analysis. 
Polygenic risk score analysis 
We found evidence of a weak association between any psychotic experience and genetic liability 
indicated by PRS at a p<0.05 threshold for SNP inclusion for schizophrenia (OR=1.09; 95% 
CI=1.06-1.12; adjusted R2=0.001; p=2.96x10-11), major depressive disorder (OR=1.16; 95% 
CI=1.13-1.19; R2=0.003; p=1.48x10-30), bipolar disorder (OR=1.07; 95% CI=1.04-1.10; R2=0.001; 
p=5.11x10-7), ADHD (OR=1.06; 95% CI=1.03-1.09; R2=0.0005; p=5.73x10-6) and autism spectrum 
disorder (OR=1.07; 95% CI=1.04-1.10; R2=0.001; p=1.34x10-5). These associations were stronger 
for distressing psychotic experiences (Figure 3, eTable 2) and consistent across most p-value 
thresholds (eFigures 8-9). We also considered individual psychotic symptoms and found that 
PRSs for schizophrenia, bipolar disorder, depression and ADHD were more strongly associated 
with delusions of persecution than the other psychotic symptoms (eTable 3, eFigures 10-12). 
The association with psychotic experience phenotypes for bipolar disorder PRS and major 
depressive disorder PRS remained significant in analyses controlling for schizophrenia PRS 
(eTable 4). The association with major depressive disorder PRS remained significant when 
individuals with a diagnosis of depression were removed (eTable 5). Given the potential for 
sample overlap with the training sets, PRS findings should be treated with a degree of caution. 
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Copy number variation 
Individuals reporting distressing psychotic experiences in particular had an increased burden of 
CNVs previously associated with schizophrenia (OR=2.04; 95% CI=1.39-2.98; p=2.49x10-4) and 
neurodevelopmental disorders (OR=1.75; 95% CI=1.24-2.48; p=1.41x10-3). There was evidence 
of an increased burden of these CNVs in individuals reporting any psychotic experience but not 
multiple occurrence psychotic experiences (Table 2).  
 
Discussion 
We conducted the largest genetic-association study of psychotic experiences using the 
population-based UK Biobank sample and found evidence of a shared genetic aetiology 
between psychotic experiences and several psychiatric disorders, which included, but was not 
specific to, schizophrenia. Genetic correlation analysis identified significant genetic correlations 
between psychotic experiences and major depressive disorder (rg=0.46), autism spectrum 
disorder (rg=0.39), ADHD (rg=0.24) and schizophrenia (rg=0.21). PRS analyses identified 
associations between psychotic experiences and genetic liability for schizophrenia, major 
depressive disorder, bipolar disorder, ADHD and autism, and we found particular enrichment of 
these PRS scores in distressing psychotic experience and for delusions of persecution. However, 
given the possibility of sample overlap between UK Biobank and the training sets, the PRS 
findings should be treated with caution. The mechanisms underlying the high genetic 
correlation between depression and psychotic experiences cannot be discerned from our 
analysis but one possibility is that the psychotic experiences have arisen in the context of mood-
related changes, consistent with the strong associations between psychotic experiences and 
depressive symptomatology observed in population-based studies54. Nonetheless, when 
individuals with a lifetime history of depression were excluded from PRS analyses the 
association remained, indicating that the findings are not wholly attributable to depression.  
We found an increased burden of CNVs previously associated with schizophrenia and 
neurodevelopmental disorders more widely in individuals with any and distressing psychotic 
symptoms, although the association was stronger for distressing psychotic experiences. All 
schizophrenia-associated CNVs are also associated with neurodevelopmental disorders such as 
intellectual disability and autism spectrum disorder, and in fact penetrance is higher in these 
disorders43. Furthermore, CNVs in UK Biobank have been associated with a range of outcomes 
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including cognitive performance41,55 and depression56, adding strength to our findings of a lack 
of specificity for psychotic experiences genetic risk.  
A number of studies have demonstrated that psychopathology in the population is best 
described by a bifactor model with a common latent trait as well as specific traits, and that 
psychotic experiences index the more severe end of the common or shared trait57,58. Our 
findings of non-specificity of genetic risk for psychotic experiences with risk for other disorders 
are consistent with previous studies7,8,11,12. Nonetheless, despite lacking specificity, our results 
suggest that incorporating questions about distress to self-reported assessments of psychotic 
experiences may allow a more valid identification of experiences that index schizophrenia and 
major mental health disorder liability.  
In the largest GWAS analyses of psychotic experiences to date, we identified four genome-wide 
significant loci. However, consistent with other studies7,11, the heritability estimate (1.7%) was 
low and given the variance explained in our PRS analysis was also low, the findings suggest that 
understanding the genetics of psychotic experiences is unlikely to have an important impact on 
understanding the genetics of schizophrenia specifically.  
The primary GWAS findings are related to intronic variants in ANK3 and CNR2. The GWAS of any 
psychotic experience identified two significant loci, the most significant of which was indexed by 
rs10994278, an intronic variant to ANK3 (OR=1.16, p=3.06x10-8). The ANK3 gene encodes 
ankyrin-G, a protein that has been shown to regulate the assembly of voltage-gated sodium 
channels and is essential for normal synaptic function47. ANK3 is one of strongest and most 
replicated genes for bipolar disorder34, and variants within ANK3 have also been associated in 
the PGC cross-disorder GWAS40, and in a rare variant analysis of autism spectrum disorder48. 
The GWAS of distressing psychotic experiences also identified two significant loci, the most 
significant of which was indexed by rs75459873, an intronic variant to CNR2 (OR=0.66, 
p=3.78x10-8). CNR2 encodes for CB2, one of two well-characterised cannabinoid receptors (CB1 
being the other). Several lines of evidence have implicated the endocannabinoid system in 
psychiatric disorders including schizophrenia50,51 and depression52. The main psychoactive agent 
of cannabis, Δ9-tetrahydrocannabinol, can cause acute psychotic symptoms and cognitive 
impairment53. Given that cannabis use is strongly associated with psychotic experiences, we 
tested, but found no evidence for, a mediating or moderating effect of cannabis use on the 
association of rs75459873 and distressing psychotic experiences. However, whilst no evidence 
was found in this study, a mediating effect of cannabis use cannot be ruled out given the 
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relatively low power of such analyses and the potential measurement error in cannabis use 
assessed via lifetime self-report. Independent replication of genetic loci identified in this study 
will be required to further understand their role in sub-clinical psychotic experiences.  
Strengths and limitations 
Strengths of this study include the large sample size (approximately 10x that of previous 
studies), the use of an adult cohort, and the use of multiple psychotic experience phenotypes, 
which increase confidence in our findings.  
Although we used all available information to identify and remove individuals with a psychotic 
disorder, it remains possible that some individuals were not identified and remained in the 
analysis. A further limitation of this study relates to the retrospective measurement of lifetime 
psychotic experiences by self-report from an online questionnaire, as this increases the 
likelihood of measurement error. A further limitation is the evidence of a ‘healthy volunteer’ 
selection bias for the participants recruited to UK Biobank and the sample cannot be therefore 
considered representative of the general population59. We also found that the participants that 
completed the MHQ had significantly higher intelligence and lower schizophrenia, depression 
and neuroticism PRS compared to UK Biobank participants who did not complete the MHQ 
(eTable 6). Lastly, we were not able to entirely de-duplicate the UK Biobank individuals from all 
of the external datasets used for the polygenic risk score analysis and thus these findings should 
be treated with caution.  
Conclusions 
In the largest GWAS of psychotic experiences from the population-based UK Biobank sample, 
we found support for a shared genetic aetiology between psychotic experiences and several 
psychiatric disorders including schizophrenia, major depressive disorder, bipolar disorder, and 
neurodevelopmental disorders indicating that psychotic experiences are not specifically related 
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Manhattan plot for GWAS analyses of any psychotic experience, distressing psychotic 
experiences and multiple occurrence psychotic experiences. Dashed line represent the genome-





Genetic correlation analysis. Colour corresponds to the strength of the correlation (rg) and stars 
correspond to the statistical significance of the correlation (* P < 6.25 x 10-3, ** P < 1.00 x 10-4, 





























































































































Polygenic risk score (PRS) analysis. The y-axis refers to the PRS tested (schizophrenia, bipolar 
disorder, major depressive disorder, attention deficit/hyperactivity disorder (ADHD), autism 
spectrum disorder, neuroticism and intelligence) and x-axis represents the odds ratio (OR). 
Points display the OR and 95% confidence intervals (error bars) for each PRS (p < 0.05 SNP 
inclusion threshold) regressed against each psychotic experiences phenotype; any psychotic 
experience (dark blue), distressing psychotic experiences (orange) and multiple occurrence 
psychotic experiences (green). Plots displaying multiple p-value SNP inclusion thresholds are 


























Multiple Occurrence Psychotic Exper ience




Phenotype SNP CHR BP A1 OR (95% CI) P Position 
Nearest 
gene 
Any PE rs10994278 10 62009219 T 1.16 (1.10-1.23) 3.06 x 10-8 Intronic ANK3 
Any PE rs549656827 5 35349428 G 0.61 (0.50-0.73) 3.30 x 10-8 Intergenic PRLR 
Distressing PE rs75459873 1 24256312 G 0.66 (0.56-0.78) 3.78 x 10-8 Intronic CNR2 
Distressing PE rs3849810 8 53009606 A 1.22 (1.13-1.31) 4.55 x 10-8 Intergenic ST18 
 
Genome-wide significant associations (p < 5 x 10-8) from GWAS analyses. Columns represent 
GWAS phenotype (PE = psychotic experience), variant (SNP), chromosome (CHR), base position 
(BP), risk allele (A1), odds ratio (OR) and 95% confidence intervals, p-value (P), position of risk 






 Case rate (n) Control rate (n) OR (95% CI) P 
Any PE 0.010 (59/5829) 0.006 (572/115807) 1.54 (1.18-2.01) 1.60 x 10-3 
Distressing PE 0.014 (28/2046) 0.006 (572/115807) 2.04 (1.39-2.98) 2.49 x 10-4 
Multiple occurrence PE 0.009 (28/3177) 0.006 (572/115807) 1.34 (0.91-1.94) 0.144 
Neurodevelopmental disorder CNVs 
 Case rate (n) Control rate (n) OR (95% CI) P 
Any PE 0.014 (83/5829) 0.009 (1058/115807) 1.54 (1.23-1.92) 1.89 x 10-4 
Distressing PE 0.017 (34/2046) 0.009 (1058/115807) 1.75 (1.24-2.48) 1.41 x 10-3 
Multiple occurrence PE 0.012 (38/3177) 0.009 (1058/115807) 1.30 (0.92-1.78) 0.139 
 
Association of psychotic experience phenotypes with copy number variants (CNVs) previously 
associated with (i) schizophrenia and (ii) neurodevelopmental disorders (note all schizophrenia-
associated CNVs are also included in neurodevelopmental disorders). Columns represent; 
phenotype  (PE = psychotic experience), rate of CNVs in cases (those reporting a psychotic 
experience), rate of CNVs in controls (the comparator group, those who did not report a 
psychotic experience), odds ratio (OR) and 95% confidence intervals (CI), and p-value (P).  
 
